Lupin is currently trading at Rs. 1257.80, up by 7.10 points or 0.57% from its previous closing of Rs. 1250.70 on the BSE.
The scrip opened at Rs. 1252.00 and has touched a high and low of Rs. 1258.20 and Rs. 1252.00 respectively. So far 3141 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1750.00 on 29-Jul-2016 and a 52 week low of Rs. 1242.50 on 09-May-2017.
Last one week high and low of the scrip stood at Rs. 1311.95 and Rs. 1242.50 respectively. The current market cap of the company is Rs. 56486.04 crore.
The promoters holding in the company stood at 46.69%, while institutions and non-institutions held 41.24% and 12.06% respectively.
US Food and Drug Administration (FDA) has issued eight observations for Lupin’s Aurangabad unit, which was inspected between April 17 and 26, 2017. These observations pertain to some market complaints regarding contamination of the drug & its effect on the consumer, some data related issues and some manufacturing protocols not being followed.
Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.
